Lin-Quan Tang Selected Research

DNA (Deoxyribonucleic Acid)

11/2023	Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial.
1/2023	A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
1/2023	A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
11/2022	Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection.
10/2022	Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial.
8/2022	Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma.
5/2022	The Prognostic Role of Plasma Epstein-Barr Virus DNA Levels in the Middle of Intensity Modulated Radiation Therapy to Guide Cisplatin Dose Recommendation in Concurrent Chemoradiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma: A Large Cohort Study.
1/2022	Identifying distinct risks of treatment failure in nasopharyngeal carcinoma: Study based on the dynamic changes in peripheral blood lymphocytes, monocytes, N classification, and plasma Epstein-Barr virus DNA.
1/2022	Cost-Effectiveness analysis of combining plasma Epstein-Barr virus DNA testing and different surveillance imaging modalities for nasopharyngeal carcinoma patients in first remission.
1/2022	M1 stage subdivisions based on 18F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lin-Quan Tang Research Topics

Disease

109	Nasopharyngeal Carcinoma 01/2024 - 01/2013
32	Neoplasm Metastasis (Metastasis) 01/2023 - 05/2013
21	Neoplasms (Cancer) 11/2023 - 01/2013
3	Necrosis 11/2023 - 01/2019
3	Mucositis 01/2023 - 08/2017
2	Leukopenia 01/2023 - 12/2018
2	Neutropenia 01/2023 - 12/2018
2	Hearing Loss (Hearing Impairment) 01/2023 - 01/2020
2	Disease Progression 12/2021 - 11/2015
2	Thrombocytopenia (Thrombopenia) 10/2021 - 01/2018
2	Anemia 10/2021 - 01/2015
2	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 01/2021 - 01/2021
2	Xerostomia 01/2020 - 01/2013
2	Venous Thromboembolism 12/2018 - 01/2018
1	Radiation Injuries (Radiation Sickness) 11/2023
1	Tertiary Lymphoid Structures 01/2023
1	Infections 01/2023
1	Septic Shock (Toxic Shock Syndrome) 01/2023
1	Body Weight (Weight, Body) 09/2021
1	Squamous Cell Carcinoma of Head and Neck 05/2021
1	Pathologic Constriction (Stenosis) 01/2021
1	Dermatitis 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Trismus (Lockjaw) 01/2020
1	Circulating Neoplastic Cells 11/2019
1	Stomatitis 10/2019
1	Pain (Aches) 10/2019
1	Lymphadenopathy 01/2019
1	Venous Thrombosis (Deep-Vein Thrombosis) 12/2018
1	Hematologic Neoplasms (Hematological Malignancy) 11/2018
1	Vomiting 01/2018
1	Ototoxicity 01/2018
1	Anorexia 01/2018
1	Nausea 01/2018
1	Exanthema (Rash) 08/2017

Drug/Important Bio-Agent (IBA)

41	DNA (Deoxyribonucleic Acid)IBA 11/2023 - 08/2013
18	Cisplatin (Platino)FDA LinkGeneric 12/2023 - 01/2013
6	Capecitabine (Xeloda)FDA Link 01/2024 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 11/2023 - 01/2015
4	Fluorouracil (Carac)FDA LinkGeneric 01/2023 - 12/2018
4	3-nitrophenyl 3-piperidinecarboxylate (MNPC)IBA 01/2022 - 01/2016
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 08/2013
3	Docetaxel (Taxotere)FDA Link 12/2023 - 12/2018
3	Paclitaxel (Taxol)FDA LinkGeneric 11/2023 - 12/2018
3	Viral DNAIBA 01/2019 - 11/2015
2	AlbuminsIBA 01/2023 - 09/2021
2	apatinibIBA 01/2023 - 01/2023
2	Immune Checkpoint InhibitorsIBA 01/2023 - 10/2019
2	Gemcitabine FDA Link 01/2023 - 01/2020
2	LigandsIBA 01/2023 - 01/2020
2	PlatinumIBA 01/2023 - 01/2023
2	ChemokinesIBA 01/2023 - 01/2020
2	nedaplatinIBA 12/2021 - 01/2018
2	EnzymesIBA 10/2021 - 03/2016
2	Hemoglobins (Hemoglobin)IBA 09/2021 - 01/2015
2	Cetuximab (Erbitux)FDA Link 01/2019 - 08/2017
2	Proteins (Proteins, Gene)FDA Link 11/2018 - 09/2015
2	C-Reactive ProteinIBA 07/2018 - 02/2015
2	AntibodiesIBA 03/2016 - 01/2016
2	AntigensIBA 03/2016 - 01/2016
2	Immunoglobulin A (IgA)IBA 03/2016 - 01/2016
2	Complement System Proteins (Complement)IBA 03/2016 - 02/2016
2	Glycoproteins (Glycoprotein)IBA 03/2016 - 01/2016
1	toripalimabIBA 01/2024
1	Albumin-Bound Paclitaxel FDA Link 12/2023
1	130-nm albumin-bound paclitaxelIBA 12/2023
1	Liposomes (Liposome)IBA 11/2023
1	Tyrosine Kinase InhibitorsIBA 01/2023
1	camrelizumabIBA 01/2023
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2023
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2023
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2021
1	angiogeninIBA 01/2021
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Therapeutic UsesIBA 01/2020
1	Zoledronic Acid (Zometa)FDA Link 10/2019
1	Oxycodone (Oxycontin)FDA LinkGeneric 10/2019
1	nimotuzumabIBA 01/2019
1	nitazoxanide (NTZ)FDA Link 01/2019
1	AnticoagulantsIBA 12/2018
1	Taxoids (Taxanes)IBA 12/2018
1	ForminsIBA 11/2018
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 07/2018

Therapy/Procedure

34	Chemoradiotherapy 12/2023 - 01/2013
32	Radiotherapy 11/2023 - 11/2014
20	Drug Therapy (Chemotherapy) 01/2023 - 01/2013
19	Induction Chemotherapy 12/2023 - 11/2014
17	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2023 - 01/2013
13	Therapeutics 01/2024 - 01/2013
4	Neoadjuvant Therapy 01/2019 - 11/2015
3	Immunotherapy 01/2023 - 02/2015
3	Neck Dissection (Radical Neck Dissection) 11/2022 - 01/2018
2	Adjuvant Chemotherapy 12/2021 - 01/2019
2	Re-Irradiation 01/2020 - 10/2016
2	Catheters 12/2018 - 01/2018
1	TP protocol 01/2022
1	Maintenance Chemotherapy 11/2021
1	Salvage Therapy 01/2020
1	Aftercare (After-Treatment) 10/2019